Mr. Mark Orsmond reports

LIGHT AI ANNOUNCES VOTING RESULTS FROM ITS ANNUAL GENERAL MEETING

Light AI Inc. has released the results of its annual general meeting of shareholders held on Aug. 19, 2026, in Vancouver, B.C.

A total of 25,357,153 common shares of the company were represented in person or by proxy at the meeting, representing approximately 20.69 per cent of the 122,559,735 common shares issued and outstanding as at the record date of July 3, 2026.

Shareholders voted in favour of all of the matters put before the meeting, as more particularly described in the management information circular of the company filed with SEDAR+ on July 20, 2026, namely:

• Electing each of the six nominees named in the circular as directors of the company for the ensuing year;
• Appointing Shim & Associates LLP, chartered professional accountants, as auditor of the company for the ensuing year and authorizing the directors of the company to fix the auditor's remuneration; and
• Approving, by ordinary resolution of disinterested shareholders, MV Capital LP as a new control person (as such term is defined in the policies of the Cboe Canada Exchange) of the company.

Voting results are as follows.

John R. Luna and W. John Meekison were elected to the board for the first time. Emmanuel L.R. Blin and Mario Vetro did not stand for re-election at the meeting. The board and management thank Mr. Blin and Mr. Vetro for their contributions and wish them continued success in their future endeavours.

Following the meeting, the board confirmed Mr. Luna as chief executive officer, Peter Whitehead as chief innovation officer, and Mark Orsmond as chief financial officer and corporate secretary. The audit committee is composed of Mr. Meekison (chair), Steven J. Semmelmayer and Robert Cartagena.

For further information regarding the matters considered at the meeting, readers are encouraged to review the circular, a copy of which is available under the profile for the company on SEDAR+ and available on the company's website.

About Light AI Inc.

Light AI is a health care technology company focused on developing artificial-intelligence-powered software-as-a-medical-device solutions designed to support rapid, accessible clinical assessment at the point of care.

The company's core technology, Light AI QuickScan, is a device-agnostic software platform that applies proprietary artificial intelligence and machine learning algorithms to medical images to provide health care professionals with actionable clinical information within seconds. The QuickScan platform is designed to operate across compatible imaging and computing hardware, providing flexibility for integration into a range of health care devices, clinical workflows and care settings without dependence on a single proprietary hardware platform.

The first product being brought to market on the platform, Light AI QuickScan strep A, uses artificial intelligence to analyze images of the throat and provide clinical decision support regarding the likelihood of Group A streptococcus pharyngitis. QuickScan strep A is designed to provide a rapid, non-invasive assessment without requiring a throat swab or laboratory test as part of the QuickScan analysis.

Light AI is developing the QuickScan platform with the potential to support additional medical conditions and clinical applications over time. The company's long-term vision is to combine its QuickScan SaMD platform, advanced imaging and cloud-based artificial intelligence to create a scalable digital clinical lab capable of delivering rapid and accessible clinical insights across multiple diseases and conditions.

In pre-Food and Drug Administration validation studies, Light AI's strep A algorithm demonstrated 96.57-per-cent accuracy in differentiating between viral and bacterial pharyngitis, and achieved a negative predictive value of 100 per cent for Group A streptococcus. Viral and GAS pharyngitis affects hundreds of millions of people globally each year, and untreated GAS infection can result in serious complications, including rheumatic heart disease.

Light AI believes its device-agnostic software architecture and artificial intelligence platform have the potential to expand access to rapid clinical decision support across diverse health care environments worldwide.